







DIFFERENTIAL MEASUREMENT ERROR ACROSS TIME AND TREATMENT 










A thesis submitted to Johns Hopkins University in conformity with the requirements for the 









In dietary observational studies and randomized controlled trials, researchers often try to 
ascertain the relationship between nutrient intake and biological outcomes, or the effect of 
interventions on intake and other outcomes. From a study design perspective, this requires 
capturing true participant intake, but properly doing so is (nearly) impossible. Intake 
measurements often rely heavily on self-reported nutrition measurements which are an easy and 
cost-effective proxy to implement in studies, but may not accurately reflect true nutrient intake. 
Less frequently, intake measurement relies on measured biological components (such as blood or 
urine) known as biomarkers. Biomarkers, considered to be the “gold standard”, are more 
resource and financially intensive, but better represent true intake.  
When studies contain both self-reported and biomarker nutrient values (which happens 
sparingly), researchers can model the measurement error structure for self-reporting errors and 
attempt to produce less biased results for calculating true but unobservable nutrient intake. 
Previous measurement error work that investigates the relationship between biomarker and self-
reported levels has typically been at a single time point, in a single treatment group, or with 
respect to basic patient demographics. Few studies have examined the measurement error 
structure in longitudinal studies, where nutrient intake and self-reported values may change over 
the course of a study, and by treatment exposure.  
Using two longitudinal randomized controlled trials with internal validation data (urine 
biomarkers and self-reported values), we examine how self-reported sodium error changes as a 
function of time and/or treatment assignment by comparing it to measured urine sodium.    
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We find that although true sodium consumption changes across time and treatment group, 
there is essentially no evidence that the measurement error varies across time or treatment 
groups. While researchers should consider the effects of time and treatment status when 
designing longitudinal studies, more evidence is needed on how measurement error changes with 
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1.1 Nutrition Data 
As chronic disease remains a steadfast issue in public health, it is natural to focus on 
lifestyle interventions to identify promising programs to improve overall population health. In 
dietetics, researchers apply such interventions to understand how improving nutrition habits will 
affect individual well-being. In a randomized control trial (RCT), scientists use chance to decide 
who receives an intervention(s) and who is placed in a control group(s) to compare dietary 
approaches such as limiting consumption of hypertensive causing nutrients, or meeting with a 
registered dietician (treatment) to an individual with no counseling (control) and assess how 
these interventions or dietary changes influence health. From this information, we discern what 
dietary factors lead to increased (or decreased) risk for a disease outcome.  
Obtaining accurate measures of nutrient intake is important for understanding the diet and 
chronic disease relationship, or when studying participant’s eating behaviors, yet properly 
measuring food consumption with high accuracy can be difficult. Direct nutrient intake is rarely 
observed, and in dietetic studies, researchers frequently resort to two methods to measure 
nutrient intake; biomarkers and self-reported methods.   
Biomarkers are biologic components from participants, such as blood, urine, or hair 
which contain information about a person’s nutrient levels. Biomarkers are useful because they 
objectively measure intake and are considered the “ideal”. Therefore, biomarkers may be closer 
to the “truth” than self-reported methods, and hence estimate a person’s nutrient intake.  
Unfortunately, biomarkers are often expensive, invasive, and/or difficult to implement 
into a study (Kirkpatrick 2018). They place potentially greater burden on trial participants than 
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self-report measures, which may discourage people from taking part of a lifestyle trial. Thus, 
there are concerns that biomarkers can contribute to poor trial adherence and missing data 
problems (i.e., that participants will drop out of the study because of the hassle or invasiveness of 
the biomarker collection) (Prentice 2002). For these reasons, it is often infeasible to capture 
biomarker data over time in many studies. 
  On the other hand, self-reported data comes directly from the participant, where they 
inform study officials about their food consumption. This often takes the form of food frequency 
questionnaires (FFQ), where participants fill out a survey about their eating habits or 24-hour 
diet recall, where people report everything consumed over the previous day. Self-reported 
methods are more frequently implemented than biomarker measurements since these are likely 
easier, cheaper, and more convenient for the participant (Kirkpatrick 2017).  
These two methods act as “proxy” measurements of true intake, because they can be 
representative, but are potentially imprecise versions of the truth and experience two main types 
of error: systematic and random.  Systematic error, or bias, consistently departs from the truth in 
the same direction (i.e., always higher or lower), and can be hard to detect and analyzed 
statistically (NIH 2014). Systematic errors can decrease the accuracy of measurements and create 
potentially erroneous conclusions about the relationship between food intake or nutrients and 
nutrition-related diseases (Gibson 2017). Random error can create variability in the 
measurements, which may reduce precision, resulting in a loss of statistical power. However, 
random errors can be more easily corrected with statistical methodology (Thompson 2016). This 





Biomarkers are considered the “gold standard” compared to self-report (and other 
nutrient reporting methods), because while biomarkers have a random error component, they 
potentially experience less systematic error than self-reported information. Self-reported 
measures are more susceptible to both random and systematic measurement error because, even 
with the best intentions, people improperly remember the foods they ate (recall bias) or lie about 
true consumption to appear healthier to researchers (desirability bias) (Espeland 2001).  
Given these measurement challenges in nutrition and many other fields, a body of 
research around methods to deal with measurement error has grown up in statistics. We will now 
formally define measurement error, and some developed methods to correct for it. 
 
1.2 Measurement Error Models 
Biomarkers and self-reported measurements, are some examples of measurement error 
sources in nutritional epidemiology. However, many other similar instruments exist in different 
disciplines such as air pollution monitors (environmental health) or chemical balances 
(chemistry). For this paper, we focus on dietetics and nutrient applications, but these concepts 
can be extrapolated to other fields which experience measurement error.  
We start with classical measurement error(Carroll 2006).Let Xi, (a vector of length N, 
where N = number of trial participants), be the true, but unobservable value of intake for person 
i.As researchers, we can only observe Wi (where Wi = (w1,…,wn)), a proxy measurement(s) of  
Xi, such as self-reported data, in person i. Since Wi doesn’t perfectly match the true value Xi, 
some error is created such that: 
Wi = Xi + εi. 
4 
 
Where εi | Xi ~ Normal(0,𝜎𝐸
2). This means the observed dose, Wi, has higher variability 
than the true dose, Xi (Carroll 2006). In dietary studies, self-reported values generally have 
greater variability than biomarker values, and classical measurement error is a justifiable model 
in this situation. 
We can expand the classical measurement error model to include proxy measurements 
W, and additional covariates Z, assumed to be recorded without any error, like age or gender. 
Let Z be a N x K matrix, where N is the number of trial participants, and K is the number of 
recorded covariates for each participant. Now our equation resembles: 
W = X + Z + XZ + ε, E(ε| X, Z) = 0. 
 This equation says, proxy measurement W, is affected by true intake X, and covariates Z, 
i.e., BMI, gender, or age might all affect self-reported amounts. While presented as an expansion 
of classical models, many measurement error models can be expanded to include covariate 
terms. 
Another example of measurement error modelling is Berkson measurement error 
(Berkson 1950), which is more common in other disciplines, such as occupational epidemiology. 
Keeping the same notation as above, Wi  now represents a known quantity, but true intake, Xi, is 
still unknown such that: 
Xi = Wi + εi. 
Where E(εi | Wi) = 0. This model now assumes the truth has more variability than the 
estimated dose (Carroll 2006). An example would be when people get the same known radiation 




These examples are by no means an exhaustive list of measurement error models. In the 
models above, we assumed the truth and observed values were continuous variables with a linear 
relationship. For nonlinear relationships, see Carroll et al. (2006.) Additionally, measurement 
error might occur in discrete outcomes, this is known as misclassification. Misclassification, 
commonly referred to as sensitivity and specificity in epidemiology, occurs when an outcome is 
incorrectly diagnosed. One example is when an unaffected person tests positive for a disease 
they don’t have. See Braga-Neto (2009) for misclassification in genetic research or Friedman et 
al. (2000) for machine learning applications.  
Finally, any measurement error model may be subject to non-differential or differential 
error. Non-differential occurs if measurement error is the same between exposed and unexposed 
groups or between subject with and without a specified health outcome (sick vs. healthy). 
Differential measurement error occurs when measurement error is different between treatment 
groups or different for those with an outcome of interest compared to those without the outcome 
of interest (Alexander 2015). 
1.3 Correcting for Measurement Error 
 We’ll now transition from describing the measurement error dilemma, to examining ways 
to correct for it. We center our applications around measurement error structure in dietetic 
studies, but many of these concepts are applicable to other disciplines and measurement error 
models. 
Regression Calibration is one method for correcting measurement error (Carroll et al. 
1995).  To build this model, it is necessary to use a dataset which contains information on both 
participants’ self-reported intake and recovery biomarker intake. By assuming biomarkers are 
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commensurate with the “true” intake values, X, we attempt to produce less biased results 
estimating diet-outcome associations. As mentioned earlier, datasets with both biomarker and 
self-reported values are relatively rare because of implementation challenges in large 
longitudinal studies.   
Although X cannot be observed directly, researchers can use a biomarker value T, into 
the equation as a substitute and make an assumption that E(X|W, Z) closely resembles 
E(T|W,Z). Biomarkers aren’t perfect as they may have their own measurement error, but they 
can be used as a more accurate measure of X, compared to other observable measurements. This 
substitution, while not perfect, allows researchers to investigate the relationship between the 
biomarker (acting as the “truth”) and proxy self-report measurement.  
X = 𝛽0 + 𝛽1
′W + 𝛽2
′Z +  𝛽3
′  W * Z  + ε,     E(ε| W, Z) = 0. 
OR 
T = 𝛽0 + 𝛽1
′W + 𝛽2
′Z +   𝛽3
′  W * Z  + ε,     E(ε| W, Z) = 0. 
 One example of a calibration study in dietetics is Neuhouser (2008), using data from the 
Women's Health Initiative Dietary Modification Trial. In this paper, researchers used a 
calibration equation to show that age, BMI, race, and treatment assignment (albeit at one time 
point) played a role in self-reported values.  
 Simulation Extrapolation, or SIMEX, is another, possible more robust, method for 
correcting measurement error (Cook 1994). SIMEX simulates additional datasets, each with 
increasing user-induced amounts of measurement error on fitted coefficients. Each new 
simulation creates larger measurement error, and then tries to extrapolate the trends from 
7 
 
increasing measurement error datasets into the original model (Carroll 2006) to see which 
coefficients contribute the most to variability in the data.  
From Hardin (2003),  
“Regression calibration attempts to estimate the unknown covariate and then run the 
analysis of interest using this linear approximant in place of the unknown covariate. 
SIMEX, on the other hand, simulates data in order to see the effect of measurement 
error on the fitted coefficients so that we can extrapolate back to the results we would 
have if the covariate were known” 
See Shang (2012), for a more in-depth discussion, in which the author used SIMEX to 
reduce measurement error in predicting student growth percentiles. 
Again, this is not an exhaustive collection of measurement error correction methods. 
Other examples include sensitivity analysis, which investigates the plausibility of certain 
assumptions when modelling measurement error (Siddique et al. 2018), or Bayesian methods, 
which utilize simulations and Markov Chain Monte Carlo concepts (Natarajan et al. 2010). 
For the purpose of this paper, we do not attempt to build corrective models, but rather are 
interested in examining whether a simple classical measurement error model is accurate, or if in 
fact the differential measurement error might vary across time and treatment group in a 
longitudinal lifestyle intervention study.  
1.4 Application  
 The existing measurement error literature has focused more on patient demographics 
such as body mass index, gender, or race and how these affect the amount of self-reported 
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measurement error (Neuhouser 2008, Mossavar-Rahmani 2017). These studies typically examine 
measurement error at one specific time point and/or a single observational cohort.  
However, we can’t assume these measurement error patterns remain constant in 
longitudinal lifestyle interventions. Self-reporting behaviors could change over time and/or by 
treatment assignment. Those in the treatment group may become more cognizant of nutrition 
intake through intervention exposure, leading to increased reporting accuracy. Participants may 
also modify their self-reported values (even if not necessarily their true intake) to appear 
compliant with intervention recommendations, which decreases their accuracy (Espeland et al. 
2001).   
Self-reported precision could also wane over time as participants experience a fatigue 
with repeated reporting (Buzzard 1996). This fatigue causes them to be more carefree and less 
rigorous, biasing results. Conversely, as people repeatedly monitor sodium intake over time, they 
may become more accurate with increased repetitions. Thus, the structure of the measurement 
error may change over time and by treatment group, an important consideration for measurement 












Using two longitudinal lifestyle intervention trials, we examine sodium intake as a case 
study to learn about whether the measurement error structure differs across time and treatment 
group; the results can then be used to understand when it is important to consider differential 
measurement error by time or group.  
To examine self-reported measurement error over time and across treatment groups, we 
used data from two longitudinal lifestyle intervention trials: Trials of Hypertension Prevention 
(TOHP) (Whelton et al. 1992) and PREMIER: Lifestyle Interventions for Blood Pressure 
Control (Appel et al. 2003).  
These data sets are particularly useful for examining measurement error over time 
because they, unlike most nutrition trials, contain self-reported sodium intake and a sodium 
biomarker – 24-hour urine – for each participant and every time point. With this information, we 
compare the participants’ self-reported values with their directly measured urinary sodium to 
characterize the measurement error, and assess whether the error varies across treatment group 
and time.  
These internal validation datasets could be helpful to learn about potential measurement 
error in other settings, and to help researchers understand how much they may need to worry 
about differential measurement error across time and treatment.   
 
2.1 Trials of Hypertension Prevention 
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TOHP was a US based, multicenter, randomized trial of 3 years duration with 2,182 
participants testing the efficacy of a lifestyle intervention aimed at lowering diastolic blood 
pressure (DBP) in the high normal range (80 to 89 mmHg) (Satterfield et al. 1991). Participants 
were assigned to one of four treatment groups: Sodium reduction, weight reduction, stress 
management, or control. The sodium reduction group received counseling on how to reduce 
sodium consumption in everyday life. The weight reduction group received guidance on weight-
loss techniques. The stress management group were provided coping mechanisms to handle 
stressful situations. The weight loss and stress management groups did not receive any 
counseling specifically on sodium intake. The control group did not receive any particular 
intervention or information; in this sense it was similar to a “usual care” condition.  
Participants were considered eligible if they were healthy men and women, aged 30 
through 54 years, who had high normal DBP and were not taking antihypertensive drugs for the 
prior 2 months (Satterfield et al. 1991). All participants were screened three times prior to 
enrollment to check eligibility requirements and then randomized to one of the four treatment 
groups. On the third screening, a 24 hour recall was conducted, and participants provided a 24-
hour urine sample; this served as their “baseline” measurement. All participants were contacted 
again – at an unannounced point in time – 6 months and 18 months after enrollment to provide 
24-hour food recall survey and 24 hour urine biomarker for sodium consumption at each 
respective time point.  
2.2 PREMIER: Lifestyle Interventions for Blood Pressure Control 
PREMIER was also a US based, multicenter randomized trial testing the effects of 
various lifestyle intervention on blood pressure outcomes in 810 individuals.  
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Participants were randomly assigned to one of three treatment groups: Established, 
Established Plus Dash, or Advice Only. The Established group received guidance on improving 
their dietary habits (including sodium consumption) and increase physical activity. Established 
Plus Dash received an intervention similar to Established but also received education on the 
DASH diet, a diet high in fruits, vegetables and low-fat dairy products. Finally, Advice Only 
received general healthy behavior advice, but no specific counseling on sodium intake or 
physical activity levels. 
All eligible participants attended a randomization visit, where researchers randomized 
them to a group and then collected baseline measurements including two 24-hour diet recalls, 
and a 24-hour urine sample. Trial researchers contacted all participants unannounced at 6 and 18 
months after enrollment, at which point individuals again provided two 24-hour diet recalls and 
24-hour urine samples (Table 1).  
We obtained the datasets for TOHP and PREMIER through an online request from the 
National Heart, Lung, and Blood Institute BioLINCC data repository after receiving IRB 
approval through Johns Hopkins Bloomberg School of Public Health.  
For both datasets we consolidated the original treatment and control groups into new ones 
for our modelling purposes. In TOHP, only the sodium reduction group received counseling on 
sodium management. Hence, the sodium reduction cohort is the treatment group and the stress 
management, weight reduction, and original control cohorts were consolidated into a new control 
arm. For our data analyses using the PREMIER study, we included both behavioral intervention 
groups (Established, Established plus DASH) as the new treatment cohort, and used the advice 
only condition as the new control arm.  We are interested in whether participants in the sodium 
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reduction interventions, more (or less) accurately reported their actual sodium intake compared 
to those in the advice only group. 
Table 1: Study Characteristics 
 TOHP PREMIER 
Enrollment Dates 1988-1990 1999-2001 








Assessment Method 24-hour recall 
24-hour urine 
Two 24-hour recalls 
24-hour urine 





Established Plus DASH* 
Advice Only` 
N 2182 810 
% Male 70 % 38 % 
Mean Baseline BMI (sd) 27.6 (3.7) 33.1 (5.7) 
Mean Baseline Age (sd) 43 (6.5) 50 (8.9) 
Table 1: Provides overview of each study and baseline demographics.  
*Categorized as “treatment” for our modeling purposes. 







The same data cleaning procedures were used for both studies prior to analysis. First, the 
biomarker sodium values were converted to dietary sodium values by dividing urine sodium 
values by 0.86, as only 86% of sodium intake appears in urine (Holbrook et al. 1984, Willet 
2013). The dietary sodium and self-reported sodium values were both log-transformed to make 
the respective distributions approximately normal. Finally, participants with extreme energy 
intakes (<500 kcal and >3,500 kcal for women, <800 kcal and >4000 kcal for men) (Holbrook et 
al. 1984, Willet 2013) were excluded for these analyses. The exclusion criteria eliminated 
7(~1%) and 8(~1%) people from TOHP and PREMIER, respectively. 
Mixed effects linear regression was used to estimate the relationship between log 
measured urine sodium and log self-reported sodium over time, separately by treatment group, 
and to account the correlation of measures within a participant over time. We centered log self-
report [log self-report – mean log self-report at baseline] to easily compare each individual 
against the mean. We allow each individual to have a random intercept, and the (log centered) 
self-reported values to have a random slope, and used an unstructured covariance matrix. All 
missing data points were treated as “missing completely at random;” discussed further below. To 
estimate these models, we used the lme4 and lmerTest packages in R version 3.5.1 
For each trial, we started with an initial model that includes both main effects for follow-
up time, subjects self-reported intake and treatment, and two-way interactions between each pair, 
and interactions between all 3. This model also includes a random intercept and a random slope 





U𝑖𝑗 = 𝛽0 + 𝛽1 ∗ self𝑖𝑗 + 𝛽2𝕀(𝑡𝑖𝑚𝑒𝑗 = 6) + 𝛽3𝕀(𝑡𝑖𝑚𝑒𝑗 = 18) + 𝛽4𝕀(𝑡𝑖𝑚𝑒𝑗 = 6) ∗ TXi 
       + 𝛽5𝕀(𝑡𝑖𝑚𝑒𝑗 = 18) ∗ TXi + 𝛽6 ∗ self𝑖𝑗𝕀(𝑡𝑖𝑚𝑒𝑗 = 6) + 𝛽7 ∗ self𝑖𝑗𝕀(𝑡𝑖𝑚𝑒𝑗 = 18) 
       + 𝛽8 ∗ self𝑖𝑗𝕀(𝑡𝑖𝑚𝑒𝑗 = 6) ∗ TXi + 𝛽9 ∗ self𝑖𝑗𝕀(𝑡𝑖𝑚𝑒𝑗 = 18) ∗ TXi  
       + 𝑏0𝑖 +  𝑏1𝑖 ∗ self𝑖𝑗 + 𝑒𝑖𝑗 
(1) 
For each person i (i = 1,…,N), at time j (j = baseline, 6 months, 18 months), in our 
defined treatment group (TX; 0 = control, 1 = treatment) their urine measured – “true” –  sodium 
intake is represented by U where e ~ N(0, σ2). Both U and self𝑖𝑗 are log transformed values, and 
self𝑖𝑗 is centered at their baseline measurements. 𝕀() is an indicator function which takes on 
either 0 or 1. 𝑏0𝑖 is the random intercept and 𝑏1𝑖 is the random slope for each person’s centered 
self-reported values respectively. We assume 𝑏0𝑖 ~ N(0, 𝜏0
2) and 𝑏1𝑖 ~ N(0, 𝜏1
2).  
We excluded a main effect for treatment (TX) from the model because we assume 
treatment and control groups have similar sodium levels at baseline, at least in expectation 
(because of randomization).  
Including the three-way (self-reported intake by time by treatment) interactions in this 
initial model allows the relationship between urine measured sodium intake and self-reported 
sodium changes over time in the control group and allows for urine measured sodium to differ 
between the treatment and control group over time. We include a time by treatment interaction to 
examine whether the control group and treatment group have different levels of urine measured 
sodium at 6 and 18 months.  
A backwards variable selection was used to fit models to analyze these data. First, this 
initial saturated model with the three-way interaction (1) was fit. For all subsequent tests a 
significance level of 0.2 was used.   We first tested the three-way interaction 
self*time*treatment. If at least one coefficient had a p-value < 0.2, we kept both interaction 
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terms in the model. If both coefficients had p-value >0.2, we dropped them from the model and 
fit the model described in (2), which omits the 3-way interaction. 
 
The second potential model did not include the three-way interaction terms: 
U𝑖𝑗 = 𝛽0 + 𝛽1 ∗ self𝑖𝑗 + 𝛽2𝕀(𝑡𝑖𝑚𝑒𝑗 = 6) + 𝛽3𝕀(𝑡𝑖𝑚𝑒𝑗 = 18) + 𝛽4𝕀(𝑡𝑖𝑚𝑒𝑗 = 6) ∗ TXi 
       + 𝛽5𝕀(𝑡𝑖𝑚𝑒𝑗 = 18) ∗ TXi + 𝛽6 ∗ self𝑖𝑗𝕀(𝑡𝑖𝑚𝑒𝑗 = 6) + 𝛽7 ∗ self𝑖𝑗𝕀(𝑡𝑖𝑚𝑒𝑗 = 18) 
       + 𝑏0𝑖 +  𝑏1𝑖 ∗ self𝑖𝑗 + 𝑒𝑖𝑗 
(2) 
In model (2), we tested the significance of the self*time terms (𝛽6, 𝛽7), which examine 
whether the relationship between urine measured sodium and self-reported measures change over 
time, assuming any change is constant across the treatment and control groups.  Once again, if 
both coefficients had p-values > 0.2, we dropped them from the model and fitted our final model, 
Model (3): 
U𝑖𝑗 = 𝛽0 + 𝛽1 ∗ self𝑖𝑗 + 𝛽2𝕀(𝑡𝑖𝑚𝑒𝑗 = 6) + 𝛽3𝕀(𝑡𝑖𝑚𝑒𝑗 = 18) + 𝛽4𝕀(𝑡𝑖𝑚𝑒𝑗 = 6) ∗ TXi 
       + 𝛽5𝕀(𝑡𝑖𝑚𝑒𝑗 = 18) ∗ TXi + 𝑏0𝑖 +  𝑏1𝑖 ∗ self𝑖𝑗 + 𝑒𝑖𝑗 
(3) 
Model (3) allows urine measured sodium levels to change across time and treatment 
status. In this model we test the time*treatment interaction (𝛽4, 𝛽5). If both coefficients had p-
values > 0.2, we dropped them from the model.  
We then standardized the regression coefficients using the mean and standard deviation 
of the pooled (control and treatment) group at baseline. 
3.1 Covariate Modelling 
While not the main purpose of this paper, we also investigated separately how BMI and 
gender influenced measurement error structure over time and by treatment assignment. Previous 
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research has shown these attributes factor into self-reported measurement error.  We built similar 
models to those listed above, but included an additional BMI or gender interaction term with 
each previously included interaction, i.e., self*time*treatment*gender, self*time*gender. We 
then again applied the backwards variable selection process which dropped terms that are not 
statistically significant, at a 0.2 p-value threshold.   


























4.1 Descriptive Results 
First, just examining the data descriptively by comparing the biomarker and self-reported 
values, both datasets include people who over and under report by time and treatment status 
(Figure 1). The 45-degree line in each graph represents “perfect” reporting, where measured 
urine biomarker equals self-reported sodium. Those who fall above the line over report, meaning 
their measured urine sodium levels were lower than self-reported levels. Conversely, those below 
the line under report, meaning their measured urine sodium levels were higher than their self-
reported amounts. The wide scattering of points suggests a high degree of variability in reported 
sodium levels. 








Figure 1: Provides data from both studies and a predicted self-reported line based on measured urine 
sodium by time and treatment status. 45-degree line represents where measured urine equals self-reported sodium.  
 
Based on the data output from Figure 1, the linear predicted slopes are relatively equal for 
the treatment and control groups at baseline; a reasonable result since we assumed the groups 
were approximately equal at baseline. The correlation between self-reported sodium and 
measured urine sodium stays comparatively constant over time and by treatment assignment 
(Table2/Table3). The biggest discrepancy between intervention arms is the intercept location 
after baseline.  
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In the TOHP dataset, the control group and treatment group reported a mean measured 
urine sodium amount of 3827 mg of sodium at baseline. At 18 months, the control group 
averaged 364 mg less sodium compared to their baseline measurement, while the treatment 
group consumed 1506 mg less at 18 months compared to their average baseline intake (as 
measured by biomarker). Despite the difference in sodium intake between the two groups, the 
difference between self-reported sodium and measured urine biomarker at 18 months is very 
similar (a log difference of 0.19 and 0.2 respectively). 
 
Table 2: Mean log values by time and treatment in the TOHP dataset  
 Control Treatment 
 Baseline 6 mo. 18 mo. Baseline 6 mo. 18 mo. 
Mean 
Urine (sd) 
8.25 (0.45) 8.24 (0.51) 8.15 (0.52) 8.25(0.40) 7.80 (0.54) 7.75 (0.57) 
Mean Self-
Report (sd) 
8.09 (0.54) 7.96 (0.54) 7.96 (0.59) 8.11 (0.54) 7.58 (0.58) 7.55(0.60) 
Mean 
Difference 
0.16 0.28 0.19 0.14 0.22 0.2 
Correlation 0.28 0.28 0.27 0.27 0.31 0.34 
Table 2: Provides the mean for measured urine and self-reported sodium, their difference, and correlation between the two measurements in 
TOHP dataset.  
 
In the PREMIER dataset, the control group consumed an average 4359 mg of sodium, 
and the treatment group reported a mean of 4230 mg of sodium at baseline. At 18 months, the 
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control group averaged of 128 mg less sodium compared to their baseline measurement, while 
the treatment group consumed 661 mg less at 18 months compared to their average baseline 
intake (as measured by biomarker). Again, the difference between self-reported sodium and 
measured urine biomarker at 18 months is very similar (a log difference of 0.45 and 0.48 
respectively). Overall, PREMIER reports higher averages of sodium intake than TOHP. 
 
Table 3: Mean log values by time and treatment in PREMIER 
 Control Treatment 
 Baseline 6 mo. 18 mo. Baseline 6 mo. 18 mo. 
Mean 
Urine (sd) 
8.38 (0.40) 8.23 (0.44) 8.29 (0.46) 8.35 (0.45) 8.13 (0.54) 8.18 (0.47) 
Mean Self-
Report (sd) 
7.94 (0.39) 7.84 (0.45) 7.84 (0.44) 7.98 (0.39) 7.66 (0.41) 7.70 (0.42) 
Mean 
Difference 
0.44 0.39 0.45 0.37 0.47 0.48 
Correlation 0.32 0.21 0.27 0.30 0.27 0.26 
Table 2: Provides the mean for measured urine and self-reported sodium, their difference, and correlation between the two measurements in 
PREMIER dataset.  
 
 
4.2 Regression Results 
Neither the three-way interactions in model (1), nor the interactions between self-reported 
sodium levels and time in model (2) met the criteria for inclusion. As such, the final model only 
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includes the interaction between treatment and time (model 3). This model says average 
measured urine sodium changes over time (𝛽2, 𝛽3), and at different rates in the treatment group 
vs. control group (𝛽4, 𝛽5).  
 
Table 4: Standardized Regression output from model (3) 
 TOHP PREMIER 




0.29 (0.23,0.34) <0.001* 0.21 (0.17, 0.26) <0.001* 
Time 6 Control 
𝛽2 
0.03 (-0.10,0.16) 0.68 -0.24 (-0.37, -0.10) <0.001* 
Time 18 Control 
𝛽3 
-0.19 (-0.32,-0.06) 0.005* -0.08 (-0.21, 0.05) 0.23 
Time 6 Trt. 
 𝛽4 
-0.81 (-1.0, -0.63) <0.001* -0.1 (-0.26, 0.06) 0.20* 
Time 18 Trt. 
 𝛽5 
-0.65 (-0.84, -0.47) <0.001* -0.15 (-0.30, 0.0) 0.06* 
Table 2: Provides standardized beta coefficient values controlling for time and treatment assignment, with their corresponding 95% confidence 
interval and p-values.  
* Significant at 0.2 level 
 
In TOHP, there was no significant interaction between average measured urine sodium 
and the difference between baseline and 6 months in the control group (𝛽2 = 0.03), for a given 
level of self-reported sodium. There was a significant decrease for the difference between 
baseline and 18 months however, in the control group ( 𝛽3 = -0.19). For the treatment 
interventions, there was on average a significant decrease in measured urine sodium between 




In PREMIER, there was a significant decrease in average measured urine sodium at 6 
months compared to baseline (𝛽2 = -0.08) in the control group, for a given level of self-report. 
There was no significant difference between 18 months and baseline in the control group (𝛽3 = -
0.08). A significant decrease in average measured urine sodium occurred at 6 months (𝛽4 = -0.1) and 18 
months (𝛽5 = -0.15) for the treatment category.  
In both studies, the three-way interaction between time, treatment, and self-reported 
amounts were not significant, nor the two-way interaction between time and self-reported 
amount. This might indicate a lack of significant difference in systematic error between the 
treatment arms across all three time points.   
These results appear consistent with Figure 1, as the average level of self-reported 
sodium doesn’t seem to change dramatically based on treatment assignment or time point. 
However, the amount of reported measured urine sodium changes as a function of time, with a 
bigger decrease in average urine sodium in treatment group compared to the control group. 
TOHP reported less measured urine sodium than PREMIER consistent with Table 2/Table 3.  
 
4.3 Covariate Results 
 For the gender and BMI covariate models, our outcomes are consistent with previous 
work and previous results of this paper. Both covariates affect the amount of predicted urine 
sodium and self-reported sodium levels.   
 We find that self-reported values do not change as a function of time, treatment, and 
gender/BMI in both studies. Consistent with model (3), expected measured sodium levels 
decrease over time, at different rates in the treatment vs. control group, even when controlling for 
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gender/BMI. Gender and BMI both affect self-reported values regardless of treatment or time 
status. 
 Overall, males over-report self-recorded sodium values, and have higher expected urine 
sodium levels. In PREMIER, males on average over reported sodium by 10% compared to 
females, and consumed 22% more sodium than females. In TOHP, males on average over 
reported by 8% compared to females, and consumed 22% more sodium. Both studies have 
imbalanced male to female ratio, and this could influence the results.  
 In BMI, we see expected urine sodium levels increase with higher BMI, and self-reported 
values decrease with higher BMI. On average as BMI increases, people consume more sodium, 
but self-report lower amounts, leading to under reporting. In PREMIER, each 1 unit increase in 
BMI lead to a 2% increase in predicted urine sodium, but a 1% decrease in self-reported value. 
In TOHP, a 1 unit increase in BMI cause a 3% increase in predict urine sodium. The self-
reported*bmi coefficient is not significant at the 0.2 p-value threshold in TOHP. 














Differential measurement error in nutrition studies may arise when the treatment group 
self-reports with increased or decreased accuracy of sodium intake (Sanjeevi 2019). Reporting 
bias can also occur over time in longitudinal studies, and may shift depending on treatment 
status.  
Based on our regression modelling, participants’ self-reported sodium levels do not 
significantly change as a function of time and/or treatment status. If this happened, either 
(𝛽8, 𝛽9), from model (1), the self-report*time*treatment status would be significant, or, (𝛽6, 𝛽7), 
from model (2), the self-report*time interaction.  
However, from model (3) there is evidence of a relationship between sodium 
consumption and time/treatment status. Over time, lifestyle trial participants experience a 
decrease in sodium intake, with a greater reduction in urine measured sodium for the treatment 
group compared to the control group. If people perfectly reported their true intake, we would 
expect β1 = 1 and β2, β3, β4, β5 = 0. In contrast, we find that β1 ≠ 1 and β2, β3, β4, β5 < 0, an 
indication measured urine sodium levels may change over time and by treatment status. 
Discrepancies in the literature still exist about the relationship between treatment and 
self-reporting error. Even though this paper didn’t find a relationship between treatment 
assignment and self-report bias, other studies have. In the Women’s Health Eating and Living 
Study, a longitudinal randomized intervention trial with validation data (Natarajan et al. 2010), 
researchers found dietary intervention affected measurement error in self-reported outcomes 
using plasma carotenoid biomarkers. In the Women's Health Initiative Dietary Modification 
Trial, another dietary intervention trial (Neuhouser et al. 2008), participants in the control group 
under-reported protein intake at greater amounts compared to the treatment arm. There is thus 
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evidence that whether or not there is differential measurement error across time and treatment 
group may vary quite a bit across studies. 
One possible solution to address measurement error would be more internal validation 
datasets with longitudinal intervention aspects. While this route is resource intensive, it may be 
worthwhile if researchers continue to study the relationship between disease outcomes and 
nutrient intake. Perhaps a cheaper or less invasive biomarker would make creating this dataset 
more feasible. 
Another option would be more measurement error correction methods, which is why it is 
important to study how measurement error structures change over time and by treatment status. 
Siddique et al. (2018) use an assumption that the measurement error structure is time invariant, 
treatment invariant, and time and treatment invariant. Understanding how measurement errors 
structures change as a function of treatment assignment and time point might improve the 
robustness of new methods, especially when trying to generalize the results of a study to the 
population. Documenting time and treatment effects with regression calibration in  internal 
validation datasets might improve the accuracy of self-reported measures in longitudinal 
intervention trials without available biomarker data.   
5.1 Limitations 
 One large limitation of this study is the amount of missing data, as high as 28% by 18 
months in TOHP (Table 3). We assumed missing at random, but this is an extreme assumption 
given the nature of the data – a longitudinal intervention trial. The assumption is likely not fully 
accurate as people can voluntarily remove themselves from the trial for various reasons. 
Participants who drop out likely behave differently than those who stay in the trial, creating bias 
in final results. 
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Table 5: Percent Missing by Time/Treatment in each study 
 TOHP PREMIER 
 Control Treatment Control Treatment 
Baseline 1 9.5 1 9 
6 months 23 29.3 23 19.6 
18 months 18.6 27.8 15 18.7 
Table 3: Percent missing by treatment category at each timepoint in TOHP and PREMIER. 
 Additionally, both biomarker and self-reported methods experience error which can 
affect the measured intake levels. It might be difficult to quantify the amount of systematic error 
within the dataset and thus might be hard to establish how time and treatment status affect the 
true relationship between biomarker and self-reported data. 
 Finally, it’s important to know that a single intake measurement, whether its biomarker or 
self-reported, may not be representative of a person’s diet (Kahn 1995). Collecting only three 
measurement over the course of 18 months might not truly capture dietetic patterns, especially if 
the fluctuate in individuals or by seasons.  
 Documenting the measurement error structure by time and treatment in longitudinal 
studies is important if researchers want to properly measure the relationship between nutrient 
intake and disease outcome. If self-reporting habits changed based on time or treatment status, 
then lifestyle intervention trials that fail to account for this, may draw erroneous conclusions of 
their results. Additionally, if researchers attempted to improve their measurement error models 
but don’t include important covariates, like BMI, gender, time and/or treatment, this may cause 
correction issues in the statistical model, once again leading to a possibly incorrect relationship 







6.1 Covariate Models 
Listed below are models (1), (2), (3) for sex. Now we include an additional indicator - 𝕀() - with 
subscript k indicating sex (k; 0 = Female, 1 = male).  
 
U𝑖𝑗𝑘 = 𝛽0 + 𝛽1 ∗ self𝑖𝑗𝑘 + 𝛽2𝕀(𝑡𝑖𝑚𝑒𝑗 = 6) + 𝛽3𝕀(𝑡𝑖𝑚𝑒𝑗 = 18) + 𝛽4𝕀(𝑡𝑖𝑚𝑒𝑗 = 6) ∗ TXi 
       + 𝛽5𝕀(𝑡𝑖𝑚𝑒𝑗 = 18) ∗ TXi + 𝛽6 ∗ self𝑖𝑗𝑘𝕀(𝑡𝑖𝑚𝑒𝑗 = 6) + 𝛽7 ∗ self𝑖𝑗𝑘𝕀(𝑡𝑖𝑚𝑒𝑗 = 18) 
       + 𝛽8 ∗ self𝑖𝑗𝑘𝕀(𝑡𝑖𝑚𝑒𝑗 = 6) ∗ TXi + 𝛽9 ∗ self𝑖𝑗𝑘𝕀(𝑡𝑖𝑚𝑒𝑗 = 18) ∗ TXi +  𝛽10𝕀(𝑚𝑎𝑙𝑒𝑘 = 1) 
       + 𝛽11 ∗ self𝑖𝑗𝑘𝕀(𝑚𝑎𝑙𝑒𝑘 = 1) +  𝛽12𝕀(𝑡𝑖𝑚𝑒𝑗 = 6) ∗ 𝕀(𝑚𝑎𝑙𝑒𝑘 = 1) 
       + 𝛽13𝕀(𝑡𝑖𝑚𝑒𝑗 = 6) ∗ 𝕀(𝑚𝑎𝑙𝑒𝑘 = 1) +  𝛽14𝕀(𝑡𝑖𝑚𝑒𝑗 = 6) ∗ TXi ∗  𝕀(𝑚𝑎𝑙𝑒𝑘 = 1) 
       + 𝛽15𝕀(𝑡𝑖𝑚𝑒𝑗 = 18) ∗ TXi ∗  𝕀(𝑚𝑎𝑙𝑒𝑘 = 1) 
       + 𝛽16 ∗ self𝑖𝑗𝑘𝕀(𝑡𝑖𝑚𝑒𝑗 = 6)  ∗  𝕀(𝑚𝑎𝑙𝑒𝑘 = 1) 
       + 𝛽17 ∗ self𝑖𝑗𝑘𝕀(𝑡𝑖𝑚𝑒𝑗 = 18) ∗  𝕀(𝑚𝑎𝑙𝑒𝑘 = 1) 
       + 𝛽18 ∗ self𝑖𝑗𝑘𝕀(𝑡𝑖𝑚𝑒𝑗 = 6) ∗ TXi  ∗  𝕀(𝑚𝑎𝑙𝑒𝑘 = 1) 




U𝑖𝑗𝑘 = 𝛽0 + 𝛽1 ∗ self𝑖𝑗𝑘 + 𝛽2𝕀(𝑡𝑖𝑚𝑒𝑗 = 6) + 𝛽3𝕀(𝑡𝑖𝑚𝑒𝑗 = 18) + 𝛽4𝕀(𝑡𝑖𝑚𝑒𝑗 = 6) ∗ TXi 
       + 𝛽5𝕀(𝑡𝑖𝑚𝑒𝑗 = 18) ∗ TXi + 𝛽6 ∗ self𝑖𝑗𝑘𝕀(𝑡𝑖𝑚𝑒𝑗 = 6) + 𝛽7 ∗ self𝑖𝑗𝑘𝕀(𝑡𝑖𝑚𝑒𝑗 = 18) 
       + 𝛽8 ∗ self𝑖𝑗𝑘𝕀(𝑡𝑖𝑚𝑒𝑗 = 6) ∗ TXi + 𝛽9 ∗ self𝑖𝑗𝑘𝕀(𝑡𝑖𝑚𝑒𝑗 = 18) ∗ TXi +  𝛽10𝕀(𝑚𝑎𝑙𝑒𝑘 = 1) 
       + 𝛽11 ∗ self𝑖𝑗𝑘𝕀(𝑚𝑎𝑙𝑒𝑘 = 1) +  𝛽12𝕀(𝑡𝑖𝑚𝑒𝑗 = 6) ∗ 𝕀(𝑚𝑎𝑙𝑒𝑘 = 1) 
       + 𝛽13𝕀(𝑡𝑖𝑚𝑒𝑗 = 6) ∗ 𝕀(𝑚𝑎𝑙𝑒𝑘 = 1) +  𝛽14𝕀(𝑡𝑖𝑚𝑒𝑗 = 6) ∗ TXi ∗  𝕀(𝑚𝑎𝑙𝑒𝑘 = 1) 
       + 𝛽15𝕀(𝑡𝑖𝑚𝑒𝑗 = 18) ∗ TXi ∗  𝕀(𝑚𝑎𝑙𝑒𝑘 = 1) 
       + 𝛽16 ∗ self𝑖𝑗𝑘𝕀(𝑡𝑖𝑚𝑒𝑗 = 6)  ∗  𝕀(𝑚𝑎𝑙𝑒𝑘 = 1) 
       + 𝛽17 ∗ self𝑖𝑗𝑘𝕀(𝑡𝑖𝑚𝑒𝑗 = 18) ∗  𝕀(𝑚𝑎𝑙𝑒𝑘 = 1) 








U𝑖𝑗𝑘 = 𝛽0 + 𝛽1 ∗ self𝑖𝑗𝑘 + 𝛽2𝕀(𝑡𝑖𝑚𝑒𝑗 = 6) + 𝛽3𝕀(𝑡𝑖𝑚𝑒𝑗 = 18) + 𝛽4𝕀(𝑡𝑖𝑚𝑒𝑗 = 6) ∗ TXi 
       + 𝛽5𝕀(𝑡𝑖𝑚𝑒𝑗 = 18) ∗ TXi  +  𝛽6𝕀(𝑚𝑎𝑙𝑒𝑘 = 1) 
       + 𝛽7 ∗ self𝑖𝑗𝑘𝕀(𝑚𝑎𝑙𝑒𝑘 = 1) +  𝛽8𝕀(𝑡𝑖𝑚𝑒𝑗 = 6) ∗ 𝕀(𝑚𝑎𝑙𝑒𝑘 = 1) 
       + 𝛽9𝕀(𝑡𝑖𝑚𝑒𝑗 = 6) ∗ 𝕀(𝑚𝑎𝑙𝑒𝑘 = 1) +  𝛽10𝕀(𝑡𝑖𝑚𝑒𝑗 = 18) ∗ TXi ∗  𝕀(𝑚𝑎𝑙𝑒𝑘 = 1) 
       + 𝛽11𝕀(𝑡𝑖𝑚𝑒𝑗 = 18) ∗ TXi ∗  𝕀(𝑚𝑎𝑙𝑒𝑘 = 1) 




For BMI, we include a subscript l to indicate a participant’s BMI (continuous) value. BMI was 
centered with respected to all (both treatment and control) participant’s baseline BMI level.  
 
U𝑖𝑗𝑙 = 𝛽0 + 𝛽1 ∗ self𝑖𝑗𝑙 + 𝛽2𝕀(𝑡𝑖𝑚𝑒𝑗 = 6) + 𝛽3𝕀(𝑡𝑖𝑚𝑒𝑗 = 18) + 𝛽4𝕀(𝑡𝑖𝑚𝑒𝑗 = 6) ∗ TXi 
       + 𝛽5𝕀(𝑡𝑖𝑚𝑒𝑗 = 18) ∗ TXi + 𝛽6 ∗ self𝑖𝑗𝑙𝕀(𝑡𝑖𝑚𝑒𝑗 = 6) + 𝛽7 ∗ self𝑖𝑗𝑙𝕀(𝑡𝑖𝑚𝑒𝑗 = 18) 
       + 𝛽8 ∗ self𝑖𝑗𝑙𝕀(𝑡𝑖𝑚𝑒𝑗 = 6) ∗ TXi + 𝛽9 ∗ self𝑖𝑗𝑙𝕀(𝑡𝑖𝑚𝑒𝑗 = 18) ∗ TXi +  𝛽10 ∗ BMIl 
       + 𝛽11 ∗ self𝑖𝑗𝑙𝕀 ∗ BMIl + 𝛽12𝕀(𝑡𝑖𝑚𝑒𝑗 = 6) ∗ BMIl 
       + 𝛽13𝕀(𝑡𝑖𝑚𝑒𝑗 = 18) ∗ BMIl + 𝛽14𝕀(𝑡𝑖𝑚𝑒𝑗 = 6) ∗ TXi ∗  BMIl 
       + 𝛽15𝕀(𝑡𝑖𝑚𝑒𝑗 = 18) ∗ TXi ∗  BMIl 
       + 𝛽16 ∗ self𝑖𝑗𝑙𝕀(𝑡𝑖𝑚𝑒𝑗 = 6) ∗  BMIl 
       + 𝛽17 ∗ self𝑖𝑗𝑙𝕀(𝑡𝑖𝑚𝑒𝑗 = 18) ∗ BMIl 
       + 𝛽18 ∗ self𝑖𝑗𝑙𝕀(𝑡𝑖𝑚𝑒𝑗 = 6) ∗ TXi  ∗  BMIl 




U𝑖𝑗𝑙 = 𝛽0 + 𝛽1 ∗ self𝑖𝑗𝑙 + 𝛽2𝕀(𝑡𝑖𝑚𝑒𝑗 = 6) + 𝛽3𝕀(𝑡𝑖𝑚𝑒𝑗 = 18) + 𝛽4𝕀(𝑡𝑖𝑚𝑒𝑗 = 6) ∗ TXi 
       + 𝛽5𝕀(𝑡𝑖𝑚𝑒𝑗 = 18) ∗ TXi + 𝛽6 ∗ self𝑖𝑗𝑙𝕀(𝑡𝑖𝑚𝑒𝑗 = 6) + 𝛽7 ∗ self𝑖𝑗𝑙𝕀(𝑡𝑖𝑚𝑒𝑗 = 18) 
       + 𝛽8 ∗ BMIl  +  𝛽9 ∗ self𝑖𝑗𝑙 ∗ BMIl + 𝛽10𝕀(𝑡𝑖𝑚𝑒𝑗 = 6) ∗ BMIl 
       + 𝛽11𝕀(𝑡𝑖𝑚𝑒𝑗 = 18) ∗ BMIl + 𝛽12𝕀(𝑡𝑖𝑚𝑒𝑗 = 6) ∗ TXi ∗  BMIl 
       + 𝛽13𝕀(𝑡𝑖𝑚𝑒𝑗 = 18) ∗ TXi ∗  BMIl 
       + 𝛽14 ∗ self𝑖𝑗𝑙𝕀(𝑡𝑖𝑚𝑒𝑗 = 6) ∗  BMIl 
       + 𝛽15 ∗ self𝑖𝑗𝑙𝕀(𝑡𝑖𝑚𝑒𝑗 = 18) ∗ BMIl 





U𝑖𝑗𝑙 = 𝛽0 + 𝛽1 ∗ self𝑖𝑗𝑙 + 𝛽2𝕀(𝑡𝑖𝑚𝑒𝑗 = 6) + 𝛽3𝕀(𝑡𝑖𝑚𝑒𝑗 = 18) + 𝛽4𝕀(𝑡𝑖𝑚𝑒𝑗 = 6) ∗ TXi 
       + 𝛽5𝕀(𝑡𝑖𝑚𝑒𝑗 = 18) ∗ TXi + 𝛽6 ∗ BMIl  +  𝛽7 ∗ self𝑖𝑗𝑙 ∗ BMIl 





6.2 Covariate Output 
 








Supp. Figure 1: Descriptive data comparing males and females with their measured urine vs. self-reported values in both datasets.  
 
Supplementary Table 1: Standardized Regression output from BMI model (3)  
 TOHP PREMIER 




0.28 (0.23,0.34) <0.001* 0.20 (0.16, 0.25) <0.001* 
Time 6 Control 
𝛽2 
0.03 (-0.10,0.16) 0.63 -0.24 (-0.37, -0.10) <0.001* 
Time 18 Control 
𝛽3 
-0.17 (-0.30,-0.04) 0.01* -0.07 (-0.20, 0.06) 0.26 
Time 6 Trt. 
𝛽4 
-0.82 (-1.0, -0.64) <0.001* -0.11 (-0.27, -0.05) 0.16* 
Time 18 Trt. 
𝛽5 
-0.68 (-0.86, -0.49) <0.001* -0.16 (-0.31, -0.01) 0.04* 
Centered BMI 
𝛽6 




Self * BMI 
𝛽7 
0.02 (-0.03, 0.07) 0.5 -0.04 (-0.08,0.0) 0.07* 
Table 1: Provides standardized beta coefficient values controlling for time and treatment assignment, and sex, with their corresponding 95% 
confidence interval and p-values.  




Supplementary Table 2: Standardized Regression output from sex model (3)  
 TOHP PREMIER 




0.18 (0.07,0.28) <0.001* 0.16 (0.10, 0.21) <0.001* 
Time 6 Control 
𝛽2 
-0.03 (-0.28,0.22) 0.80 -0.18 (-0.36, -0.01) 0.04* 
Time 18 Control 
𝛽3 
-0.16 (-0.41,0.09) 0.22 -0.11 (-0.28, 0.05) 0.18* 
Time 6 Trt. 
𝛽4 
-0.74 (-1.10, -0.38) <0.001* -0.01 (-0.21, 0.09) 0.93 
Time 18 Trt. 
𝛽5 
-0.75 (-1.10, -0.39) <0.001* -0.01 (-0.20, 0.18) 0.92 
Male 
𝛽6 
0.48 (0.29, 0.66) <0.001* 0.46 (0.31, 0.60) <0.001* 
Centered 
Self * Male 
𝛽7 
0.11 (-0.02, 0.23) 0.09* 0.07 (-0.02,0.16) 0.15* 
Male *Time 6 
Control  
𝛽8 
0.06 (-0.23,0.35) 0.69 -0.19 (-0.47, 0.09) 0.19* 
Male *Time 18 
Control 
 𝛽9 
-0.07 (-0.37,0.22) 0.63 0.06 (-0.20, 0.33) 0.63 
32 
 
Male * Time 6 
Trt. 
𝛽10 
-0.13 (-0.55, 0.29) 0.54 -0.26 (-0.59, -0.07) 0.12* 
Male * Time 18 
Trt. 
𝛽11 
0.10 (-0.32, 0.52) 0.66 -0.38 (-0.69, -0.07) 0.01* 
Table 2: Provides standardized beta coefficient values controlling for time and treatment assignment, and sex, with their corresponding 95% 
confidence interval and p-values.  
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